diss_wolf_theresa.pdf (2449 KB) - Ernst-Moritz-Arndt-Universität ...

152 Literatur
Leumann, L., Feldon, J., Vollenweider, F.X. & Ludewig, K. (2002). Effects of typical and
atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia.
Biological Psychiatry, 52(7), 729-739
Lezak, M.D., Howieson, D.B. & Loring, D.W. (2004). Neuropsychological Assessment (4 rd
edition). New York, Oxford: Oxford University Press
Liddle, P.F. (1987). The symptoms of chronic schizophrenia: a re- examination of the positive-
negative dichotomy. British Journal of Psychiatry, 151, 145-151
Liechti, M.E., Geyer, M.A., Hell, D. & Vollenweider, F.X. (2001). Effects of MDMA (ecstasy)
on prepulse inhibition and habituation of startle in humans after pretreatment
with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology, 24(3), 240-
252
Liem-Moolenaar, M., Rad, M., Zamuner, S., Cohen, A.F., Lemme, F., Franson, K.L., van
Gerven, J.M. & Pich, E.M. (2011). Central nervous system effects of the interaction
between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated
doses) in healthy men. British journal of psychopharmacology, 71(6), 907-916
Light, G.A. & Braff, D.L. (1999). Human and animal studies of schizophrenia- related gating
deficits. Current Psychiatry Reports, 1(1), 31-40
Light, G.A. & Braff, D.L. (2001). Measuring P50 suppression and prepulse inhibition in a
single recording session. American journal of psychiatry, 158(12), 2066-2068
Light, G.A., Swerdlow, N.R., Rissling, A.J., Radant, A., Sugar, C.A., Sprock, J., Pela, M.,
Geyer, M.A. & Braff, D.L. (2012). Characterization of neurophysiologic and neurocognitive
biomarkers for use in genomic and clinical outcome studies of schizophrenia.
PLoS ONE, 7(7), e39434
Ludewig, K. & Vollenweider,F.X. (2002). Impaired sensorimotor gating in schizophrenia
with deficit and with nondeficit syndrome. Swiss medical weekly, 132(13-14), 159-
165
Ludewig, K., Geyer, M.A. & Vollenweider, F.X. (2003). Deficits in prepulse inhibition and
habituation in never-medicated, first- episode schizophrenia. Biological Psychiatry,
54, 121-128